MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma
Talquetamab, an antibody that pulls T cells onto a new myeloma target called GPRC5D, produced responses in about seven in ten heavily pretreated patients, including those already treated with BCMA-directed therapy.
Overview
Phase 1 dose-escalation and expansion study of 288 patients with relapsed or refractory multiple myeloma treated with subcutaneous talquetamab at 405 micrograms per kilogram weekly or 800 micrograms per kilogram every two weeks.
Response rates were about 70 percent at both doses with a median duration of response of about 10 months; cytokine release syndrome was common but mostly low grade, and skin, nail and taste changes were characteristic.
- Overall response about 70 percent at the two recommended doses.
- Median duration of response roughly 10 months; cytokine release syndrome in about three quarters, mostly grade 1 to 2.
A second bispecific target beyond BCMA gives patients an option after BCMA-directed CAR-T or bispecifics have failed; it was approved in 2023.
- Single-arm early-phase data.
- Dysgeusia, weight loss and skin toxicity affect quality of life and adherence.
Similar pages
not linked directly; found by shared links- PairingBCMA-directed therapy → GPRC5D-directed therapy
Shares MonumenTAL-1, Talquetamab, Relapsed or refractory multiple myeloma.
- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Talquetamab, Relapsed or refractory multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Talquetamab, Relapsed or refractory multiple myeloma.
- TargetGPRC5D
Shares Talquetamab, Relapsed or refractory multiple myeloma.
- Key paperMajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma
Shares Talquetamab, Relapsed or refractory multiple myeloma, New England Journal of Medicine.
- Key paperKarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma
Shares Relapsed or refractory multiple myeloma, New England Journal of Medicine.
- Key paperCARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy
Shares Relapsed or refractory multiple myeloma, New England Journal of Medicine.